thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
On 6 October 2015, Microsoft unveiled the latest version of their Microsoft Surface Book laptop with a display of "over 6 million pixels" and their new phones the Microsoft Lumia 950 and 950 XL, which, aside from 4K video recording that their predecessors included, feature a display of "over 5 million pixels". On 8 December 2015, the ceremony of the opening of the Holy Door in Vatican City, which marked the beginning of the Jubilee Year of Mercy in the Roman Catholic church, was the first worldwide Ultra HD broadcast via satellite. The event was produced by the Vatican Television Center with the support of Eutelsat, Sony, Globecast and DBW Communication. The team did some advanced experimentation with 4K/High Dynamic Range live images and in particular using technology developed by the BBC's R&D division and Japan's public broadcaster NHK in terms of Hybrid Log Gamma (HLG) signals.
=== Alternative to autograft in long bone nonunions === In 2001, the Food and Drug Administration (FDA) approved rhBMP-7 (a.k.a. OP-1; Stryker Biotech) for a humanitarian device exemption as an alternative to autograft in long bone nonunions. In 2004, the humanitarian device exemption was extended as an alternative to autograft for posterolateral fusion. In 2002, rhBMP-2 (Infuse; Medtronic) was approved for anterior lumbar interbody fusions (ALIFs) with a lumbar fusion device. In 2008 it was approved to repair posterolateral lumbar pseudarthrosis, open tibia shaft fractures with intramedullary nail fixation. In these products, BMPs are delivered to the site of the fracture by being incorporated into a bone implant, and released gradually to allow bone formation, as the growth stimulation by BMPs must be localized and sustained for some weeks. The BMPs are eluted through a purified collagen matrix which is implanted in the site of the fracture. rhBMP-2 helps grow bone better than any other rhBMP so it is much more widely used clinically. There is "little debate or controversy" about the effectiveness of rhBMP-2 to grow bone to achieve spinal fusions, and Medtronic generates $700 million in annual sales from their product.
These positive feedbacks on the aging process are counteracted by protective mechanisms: Decreased mTOR activity (among other factors) upregulates removal of dysfunctional cellular components via autophagy. mTOR is a key initiator of the senescence-associated secretory phenotype (SASP). Interleukin 1 alpha (IL1A) is found on the surface of senescent cells where it contributes to the production of SASP factors due to a positive feedback loop with NF-κB. Translation of mRNA for IL1A is highly dependent upon mTOR activity. mTOR activity increases levels of IL1A, mediated by MAPKAPK2. mTOR inhibition of ZFP36L1 prevents this protein from degrading transcripts of numerous components of SASP factors.
=== 18th–19th centuries === After 1786, the territory of the Don Cossacks was officially called Don Host Land, and was renamed Don Host Oblast in 1870 (presently part of the Rostov, Volgograd, and Voronezh regions of the Russian Federation as well as part of the Luhansk region of Ukraine). In 1805 the Don Cossack capital was shifted from Cherkassk to Novocherkassk (New Cherkassk).
Sources: en.wikipedia.org
== Further reading == Jumhawan, U.; Putri, S. P.; Yusianto; Marwani, E.; Bamba, T.; Fukusaki, E. (2013). "Selection of Discriminant Markers for Authentication of Asian Palm Civet Coffee (Kopi Luwak): A Metabolomics Approach" (PDF). Journal of Agricultural and Food Chemistry. 61 (33): 7994–8001. doi:10.1021/jf401819s. PMID 23889358. Archived from the original (PDF) on 31 May 2019. Jumhawan, U.; Putri, S. P.; Yusianto; Bamba, T.; Fukusaki, E. (2016). "Quantification of coffee blends for authentication of Asian palm civet coffee (Kopi Luwak) via metabolomics: A proof of concept". Journal of Bioscience and Bioengineering. 122 (1): 79–84. doi:10.1016/j.jbiosc.2015.12.008. PMID 26777237. Jumhawan, U.; Putri, S. P.; Yusianto; Bamba, T.; Fukusaki, E. (2015). "Application of gas chromatography/flame ionization detector-based metabolite fingerprinting for authentication of Asian palm civet coffee (Kopi Luwak)" (PDF). Journal of Bioscience and Bioengineering. 120 (5): 555–561. doi:10.1016/j.jbiosc.2015.03.005. PMID 25912451. Archived from the original (PDF) on 31 May 2019. Sulihkanti, A.; Wahyudi, T.; Tunjung Sari, A. B. (2012). "Analysis of luwak coffee volatile by using solid phase microextraction and gas chromatography (Analisa senyawa volatil kopi luwak dengan menggunakan mikroekstrasi fase padat dan kromatolgi gas)". Pelita Perkebunan. 28 (2): 111–118. doi:10.22302/iccri.jur.pelitaperkebunan.v28i2.204. Archived from the original on 22 June 2020. Retrieved 5 January 2020.
== Function == Generally, S100A12 has a significant anti-infectious and antibacterial role that is related to its ability to uptake ions. For example, it inhibits the spread and virulence of H. pylori.
== Reception == Stumptown won in the Best Coffee (Locally Roasted) category of Willamette Week's annual 'Best of Portland' readers' poll in 2006. It was a runner-up in the Best Coffee Shop category in 2017 and won in the Best Coffee Roaster category in 2018. Stumptown was a runner-up and ranked second in the Best Coffee category in 2020 and 2022, respectively. It was a finalist in the same category in 2025.
Sources: en.wikipedia.org
=== E. coli === 2,3-diDHB dehydrogenase catalyzes the NAD+-dependent oxidation of 2,3-dihydro-2,3-dihydroxybenzoate to produce an aromatic compound 2,3-dihydroxybenzoic acid (2,3-DHB or simply DHB). In times of iron deficiency, iron uptake is controlled by three genes: ent, fep, and fes for synthesis, export, and uptake of ferric Enterobactin and its hydrolytic cleavage to release Fe3+ into the cell. This production of this compound is controlled by eight genes: entA-entF, entH, and entS. In E. coli, all of these genes are controlled by the Fur repressor, such that the genes are turned on when the concentration of iron in the environment is low. From these six genes, EntA, EntB, and EntC are responsible for the synthesis of DHB from chorismic acid and the gene EntA encodes the information of 2,3-diDHB dehydrogenase. Without entA, entB, and entC, the bacteria show almost an absolute requirement of DHB in order to survive.
When the recombinant MBP includes a signal peptide, the fusion protein can be exported into the periplasmic space, which facilitates its purification since the periplasmic fluid contains only a limited number of proteins and can be recovered either by an osmotic shock or by permeabilization of the bacterial outer membrane with antibiotics such as Polymyxin B. Such an export of the fusion protein into the periplasmic space enables the formation of disulfide bonds in the passenger protein, for example antibody fragments. Foreign proteins that are exported or secreted in their native organism, can usually be exported into the E. coli periplasm by fusion with MBP. Examples of cytoplasmic proteins that could be exported by fusion with MBP, include the monomeric Klenow polymerase and the dimeric Gene V protein of phage M13. When the recombinant MBP includes either a defective or no signal peptide the fusion protein remains within the bacterial cytoplasm from where it can be recovered by breaking open the cells. The fusion of proteins with MBP usually enhances their solubility and facilitates their proper folding so that the fusion proteins are most often bifunctional. In addition, such fusions can facilitate the crystallisation of difficult proteins, e.g. membrane proteins. The crystallized protein can often have their structures solved by X-ray crystallography using molecular replacement on a known MBP structure.
=== Electromagnetic radiation === Acoustic photonic intellectual neurostimulation (APIN) Light therapy (phototherapy) Ultraviolet light therapy PUVA therapy Photodynamic therapy Photothermal therapy Pulsed electromagnetic field therapy Cytoluminescent therapy Blood irradiation therapy Laser therapy Low-level laser therapy Transcranial pulsed electromagnetic fields (tPEMF)
Opportunistic bands of Normans successfully established a foothold in southern Italy. Probably as the result of returning pilgrims' stories, the Normans entered southern Italy as warriors in 1017 at the latest. In 999, according to Amatus of Montecassino, Norman pilgrims returning from Jerusalem called in at the port of Salerno when a Muslim attack occurred. The Normans fought so valiantly that Prince Guaimar III begged them to stay, but they refused and instead offered to tell others back home of the Prince's request. William of Apulia tells that, in 1016, Norman pilgrims to the shrine of the Archangel Michael at Monte Gargano were met by Melus of Bari, a Lombard nobleman and rebel, who persuaded them to return with more warriors to help throw off the Byzantine rule, which they did. The two most prominent Norman families to arrive in the Mediterranean were descendants of Tancred of Hauteville and the Drengot family. A group of Normans with at least five brothers from the Drengot family fought the Byzantines in Apulia under the command of Melus of Bari. Between 1016 and 1024, in a fragmented political context, the County of Ariano was founded by another group of Norman knights headed by Gilbert Buatère and hired by Melus of Bari. Defeated at Cannae, Melus of Bari escaped to Bamberg, Germany, where he died in 1022. The county, which replaced the pre-existing chamberlainship, is considered to be the first political body established by the Normans in the south of Italy.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.